A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 3116-3118

  Yasuda, Mitsuru ^a   Ito, Shin ^b   Kido, Akira ^c   Hamano, Kiminari ^c   Uchijima, Yutaka ^c   Uwatoko, Noriyasu ^c   Kusuyama, Hiroyuki ^c   Watanabe, Akiko ^c   Miyamura, Ryuzou ^c   Miyata, Kazutoyo ^c   Deguchi, Takashi ^d  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b IClinic   (Japan)

^c Urological Infection Research Group in West Saitama   (Japan)

^d GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Azithromycin SR; Male urethritis; Neisseria gonorrhoeae

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; BACTERIAL CLEARANCE; CLINICAL OUTCOME; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GONOCOCCAL URETHRITIS; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NEISSERIA GONORRHOEAE; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION; ADMINISTRATION AND DOSAGE; DELAYED RELEASE FORMULATION; DRUG EFFECTS; GONORRHEA; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; URETHRITIS; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DELAYED-ACTION PREPARATIONS; GONORRHEA; HUMANS; MALE; MIDDLE AGED; NEISSERIA GONORRHOEAE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URETHRITIS; YOUNG ADULT;

EID: 84929910870     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku221     Document Type: Article

References (20)

1. CDC. 1989 sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep 1989; 38 Suppl 8: 1-43.
2. CDC. 1993 sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 1993; 42(RR-14): 1-102.
3. Deguchi T, Saito I, Tanaka M et al. Fluoroquinolone treatment failure in gonorrhea. Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones. Sex Transm Dis 1997; 24: 247-50.
4. Yokoi S, Deguchi T, Ozawa T et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13: 1275-7.
5. Ohnishi M, Saika T, Hoshina S et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011; 17: 148-9.
6. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J Antimicrob Chemother 1993; 31 Suppl E: 193-8.
7. Ehret JM, Nims LJ, Judson FN. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Sex Transm Dis 1996; 23: 270-2.
8. Dillon JA, Rubabaza JP, Benzaken AS et al. Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998. Sex Transm Dis 2001; 28: 521-6.
9. Galarza PG, Alcalá B, Salcedo C et al. Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina. Sex Transm Dis 2009; 36: 787-8.
10. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86: 422-6.
11. Liu P, Allaudeen H, Chandra R et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007; 51: 103-9.
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI, Wayne, PA, USA, 2012.
13. Handsfield HH, McCutchan JA, Corey L et al. Evaluation of new antiinfective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1: S123-30.
14. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl 1: S47-65.
15. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148: 606-13.
16. Newman LM, Moran JS,Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 Suppl 3: S84-101.
17. Tapsall JW, Shultz TR, Limnios EA et al. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex Transm Dis 1998; 25: 505-8.
18. Kirkcaldy RD, Kidd S, Weinstock HS et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013; 89 Suppl 4: iv5-10.
19. Yasuda M, Ito S, Miyata K et al. In vitro antibacterial susceptibility and drug interaction studies: susceptibilities of Neisseria gonorrhoeae to antimicrobial agents from 2000 to 2011 in Japan. In: Abstracts of the Twenty-eighth International Congress of Chemotherapy and Infection, Yokohama, Japan, 2013. Abstract P-109. International Society for Chemotherapy, Aberdeen, Scotland, UK.
20. Wada K, Uehara S, Mitsuhata R et al. Prevalence of pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae among heterosexual men in Japan. J Infect Chemother 2012; 18: 729-33.